 |
| Company |
Product name
/number |
Product
type |
Phase of development |
Status and
comment
February 2000 |
| PC |
I |
II |
III |
L |
|
| Aventis
|
Fenchylamine sulfonamides
|
Gamma-secretase inhibitors
|
 |
|
|
|
|
|
|
| Aventis
|
M-100907B
|
5HT2 blocker
|
|
 |
|
|
|
|
|
| Boehringer Ingelheim
|
Talsaclidine
|
Stimulator of muscarinic
M1 receptors
|
|
|
 |
|
|
|
|
|
Cambridge Antibody Technology
|
Monoclonal antibody
|
Anti-plaque antibodies
|
|
|
|
|
|
Joint research venture
with Wyeth
|
|
|
Cephalon Inc
|
CEP-1347
|
Neuro-protectant
|
|
|
|
|
|
|
|
Cortex
Pharmaceuticals
|
Ampakine (CX-516)
|
AMPA receptor mediator
|
|
|
|
|
|
|
|
Daiichi
Pharmaceuticals
|
Nefiracetam
|
Stimulates ACh N-type
receptors
|
|
|
|
 |
|
For Japanese market only
|
|
| Dainippon Pharma
|
Posatirelin
|
Neuro-protectant –acts
on ACh-processing enzymes
|
|
|
|
|
|
|
|
Ebewe
Pharmaceuticals
|
Cerebrolysin (FPF-1070)
|
Peptides with NGF-like actions
and other properties
|
|
|
|
|
|
|
|
| Eisai & Pfizer
|
Donepezil
|
ACh esterase inhibitor
|
|
|
|
|
 |
|
|
| Elan Corporation
|
AN-1792
|
Beta-amyloid peptide vaccine
|
|
|
|
|
|
With Janssen
|
|
| Eli Lilly & Company
|
DAPT
|
Gamma-secretase inhibitor
|
|
|
|
|
|
|
|
| GlaxoSmithKline
|
GW-253035
|
Selective COX-2 inhibitor
|
|
|
|
|
|
|
| |
SB 271046
|
5HT6 blocker
|
|
|
|
|
|
|
|
| Merck Sharp & Dohme
|
Rofecoxib
|
NSAID and selective COX-2
inhibitor
|
|
|
|
|
|
|
| |
Peptide mimetic series
|
Gamma-secretase inhibitors
|
|
|
|
|
|
|
|
| Merz & Company
|
Memantine
|
NMDA receptor blocker
|
|
|
|
|
|
Co-development for Europe
with Lundbeck A/S
|
|
| NeoTherapeutics
|
Leteprinim (AIT-082)
|
Generates neurotrophins
by second messenger stimulation
|
|
|
|
|
|
|
|
| Novartis
|
Rivastigmine
|
ACh esterase inhibitor
|
|
|
|
|
|
|
| |
NDD 094
|
|
|
|
|
|
|
|
| |
DHEA
|
Steroidal neuro-protectant
|
|
|
|
|
|
Co-development with Neurocrine
Biosciences Ltd
|
|
| Nymox
|
NXD 2858
|
Anti-plaque agent
|
|
|
|
|
|
|
|
| Pfizer
|
Tacrine
|
ACh esterase inhibitor
|
|
|
|
|
|
Available in US, not in
the UK
|
| |
CI-1017
|
Selective stimulator of
M1 receptors
|
|
|
|
|
|
|
| |
NGD 97-1
|
GABA receptor inverse
agonist
|
|
|
|
|
|
Co-development with Neurogen
Inc
|
|
| Pharmacia
|
Celecoxib
|
NSAID and selective COX-2
inhibitor
|
|
|
|
|
|
|
|
| Sanofi-Synthélabo
|
SL 25.1188
|
Monoamine oxidase B inhibitor
|
|
|
|
|
|
|
| |
SL-65.0102
|
Acts on presenilin genes?
|
|
|
|
|
|
|
| |
Xaliproden
|
Anti-neuro-degenerative
agent
|
|
|
|
|
|
|
| |
SR 57746
|
NGF-like properties
|
|
|
|
|
|
|
|
| Shire
|
Galantamine
|
ACh esterase inhibitor
|
|
|
|
|
|
Also enhances function
of nicotine receptors. Co-development with Janssen
|
|
| SIBIA Neurosciences Inc
|
SIB-1553A
|
Nicotine and ACh receptor
stimulator
|
|
|
|
|
|
|
|
| Sigma Tau
Pharmaceuticals
|
Acetyl L-carnitine
|
Reduces age-related
damage in mitochondrial function
|
|
|
|
|
|
|
|
Taiko
Pharmaceutical Company
|
GTS-21
|
Nicotine receptor
stimulator
|
|
|
|
|
|
|
|
| Takeda
|
TAK-147
|
ACh choline esterase inhibitor
with NGF-like properties
|
|
|
|
|
|
Related to galantamine
|
|
| Various
|
Ibuprofen
|
NSAID
|
|
|
|
|
|
Studies sponsored by Wyeth,
Upjohn and Bristol-Myers Squibb
|
|
| Academic
|
OM992
|
Beta-secretase inhibitor
|
|
|
|
|
|
|
|
| Academic
|
Clioquinol
|
Heavy metal chelator
|
|
|
|
|
|
|
|
